Objective: Pneumococcal illnesses affect over one million Americans annually, making invasive pneumococcal disease (pneumonia) the most prevalent vaccine-preventable illness. Despite well-documented vaccine safety and efficacy, pneumococcal vaccine (PPSV23) uptake remains low, particularly among minorities. This study sought to define variables predicting PPSV23 uptake in eligible African-American (AA) adults.
Design And Sample: This was a cross-sectional study using a combined version of the Health Belief (HBM) and Precaution Adoption Process Models (PAPM). A convenience sample of 295 AA adults self-administered the Vaccine Uptake Questionnaire (VUQ).
Measures: Bivariate chi-square analyses were conducted and significant variables evaluated using backward stepwise logistic regression.
Results: PPSV23 uptake was 32.2% (n = 95). Older age, female gender, vaccine awareness, increased knowledge, higher trust scores, perceived susceptibility, and presence of provider recommendation for PPSV23 predicted vaccine uptake. In regression modeling, age, awareness, and provider recommendation remained significant predictors with younger age, unawareness, and lack of provider recommendation decreasing the likelihood of vaccination.
Conclusion: Three dimensions of the HBM (barriers, cues, and susceptibility) predicted PPSV23 uptake. With 147 (47.8%) unaware of PPSV23 existence prior to this study, adding the dimension "unaware" from the PAPM may strengthen the model and assist efforts to increase PPSV23 uptake among AA adults.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/phn.12257 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pneumococcal vaccination, but not influenza vaccination, is negatively associated with incident dementia among Japanese older adults: The JAGES 2013-2022 prospective cohort study.
Brain Behav Immun
August 2024
Department of Social Preventive Medical Sciences, Center for Preventive Medical Sciences, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba 360-0856, Japan; Department of Gerontological Evaluation, Center for Gerontology and Social Science, Research Institution, National Center for Geriatrics and Gerontology, Aichi, Japan. Electronic address:
Background: It is unclear whether inactivated influenza vaccination (IIV) or pneumococcal vaccination are associated with the risk of dementia; however, both types of vaccination are recommended for older adults. Studies have shown that the IIV is negatively associated with incident dementia; however, the uptake of pneumococcal vaccinations has not been considered. We investigated the independent associations of IIV and 23-valent pneumococcal polysaccharide vaccine (PPSV23) with incident dementia in older adults.
View Article and Find Full Text PDFPneumococcal vaccine uptake in patients with inflammatory arthritis: a single centre cohort study.
Rheumatology (Oxford)
June 2024
Centre for rheumatic disease, King's College London, UK.
Introduction: Current guidelines recommend pneumococcal vaccination in individuals who are over the age of 65 or are immunosuppressed due to a disease or treatment. The objective of this study was to assess vaccine uptake rates in people with inflammatory arthritis for the pneumococcal, influenza and Covid-19 vaccines and factors determining uptake.
Methods: We conducted a retrospective single centre cohort study in the UK of individuals with rheumatoid arthritis, psoriatic arthritis and axial spondylarthritis between October and December 2023.
Changes in the cost-effectiveness of pneumococcal vaccination and of programs to increase its uptake in U.S. older adults.
J Am Geriatr Soc
August 2024
Departments of Medicine and Family Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Background: Multiple factors, such as less complex U.S. adult pneumococcal recommendations that could increase vaccination rates, childhood pneumococcal vaccination indirect effects that decrease adult vaccination impact, and increased vaccine hesitancy (particularly in underserved minorities), could diminish the cost-effectiveness of programs to increase pneumococcal vaccination in older adults.
View Article and Find Full Text PDFCost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine Among US Children with Underlying Medical Conditions.
Infect Dis Ther
April 2024
Avalere Health, Boston, MA, USA.
Introduction: A 20-valent pneumococcal conjugate vaccine (PCV20) was recently recommended for use among US children. We evaluated the cost-effectiveness of PCV20 among children aged 6 years with chronic medical conditions (CMC+) and children aged 6 years with immunocompromising conditions (IC) versus one and two doses of 23-valent pneumococcal polysaccharide vaccine (PPSV23), respectively.
Methods: A probabilistic model was employed to depict 10-year risk of clinical outcomes and economic costs of pneumococcal disease, reduction in life years from premature death, and expected impact of vaccination among one cohort of children with CMC+ and IC aged 6 years.
Compliance with recommended pneumococcal vaccination schedule in patients treated for rheumatoid arthritis: A retrospective cohort study in the Veterans Affairs population.
Vaccine
January 2024
VA North Texas Health Sciences Center, Dallas, TX, United States; UCONN School of Medicine, Farmington, CT, United States.
Introduction: Invasive pneumococcal disease (IPD) is a leading cause of death. Rheumatoid arthritis (RA) patients are at risk of IPD due to immunosuppressant medications. Up until 2022, two pneumococcal vaccines, the 13-valent Pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23), were recommended.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!